Therapixel
Therapixel is a French AI software company that develops and sells MammoScreen, an FDA-cleared and CE-marked deep learning SaaS application that assists radiologists in detecting breast cancer on 2D and 3D screening mammograms, serving hospitals, IDNs, and imaging networks.
- Company typePrivate
- Founded2013
- HeadquartersNice, France
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Therapixel does
Therapixel is a privately held French software company founded in 2013 in Nice by INRIA researchers Pierre Fillard and Olivier Clatz, focused exclusively on artificial intelligence for medical imaging, specifically breast cancer screening. Its sole commercial product, MammoScreen, is an FDA-cleared (510(k) K192854 for 2D in 2020 and K211541 for 3D Digital Breast Tomosynthesis in 2021) and CE-marked (January 2021) deep learning computer vision application that automatically detects and characterizes suspicious lesions and calcifications on mammograms and assigns a 1–10 MammoScreen Score indicating malignancy probability. The system is trained on a proprietary database of more than 8 million images, supports explainable AI outputs, and compares current exams against prior mammograms to refine predictions; clinical studies published in Radiology: AI demonstrated an AUC improvement from 0.769 to 0.797 and a sensitivity gain of +0.033 (P = .021) when radiologists used the tool.
The company sells MammoScreen through a SaaS subscription model with quote-based, multi-year enterprise licensing, targeting radiology departments, breast imaging centers, healthcare provider networks (IDNs), and organized national screening programs. Distribution combines direct enterprise field sales with channel and OEM partnerships, including deployments via Onsite Women's Health (150+ US sites), Mayo Clinic radiology departments, and a PACA-region study with CRCDC Sud PACA in France. The company employs 51–100 people across offices in Nice (headquarters), Paris, and Chicago, has raised more than €20 million across Series A (€5M, 2019) and Series B (€15M, 2022), and is ISO/IEC 27001 and GDPR compliant.
Therapixel firmographics
Firmographics- Name
- Therapixel
- Legal name
- Therapixel SA
- Website
- https://therapixel.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Therapixel is a French AI software company that develops and sells MammoScreen, an FDA-cleared and CE-marked deep learning SaaS application that assists radiologists in detecting breast cancer on 2D and 3D screening mammograms, serving hospitals, IDNs, and imaging networks.
- Ownership category
- akta.pro rank
Therapixel industry classification
Industry- Product category
- Medical Imaging AI Software
- NAICS
- Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industries
- Mammography & Breast Imaging Systems (HLAHABAF), Women’s Imaging & Breast Health Centers (HLAFAJAJ)
Keywords
Where Therapixel is headquartered
LocationHeadquarters
- HQ city
- Nice
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Therapixel business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- SaaS Subscription Model: Therapixel operates on a Software-as-a-Service (SaaS) subscription model for its MammoScreen AI software. Healthcare facilities pay licensing fees for access to the AI-powered mammography analysis platform. The company provides customer quotes based on facility needs and usage patterns.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise licensing for hospitals and imaging networks |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Therapixel product offering
Product offeringCore offering
Therapixel develops and sells MammoScreen, an FDA-cleared and CE-marked AI software that assists radiologists in interpreting screening mammograms (both 2D and 3D/Digital Breast Tomosynthesis). The software automatically detects and characterizes suspicious lesions and calcifications, assigns a 1-10 MammoScreen Score representing malignancy probability, and uses prior exam comparisons to improve detection of cancers that would otherwise be diagnosed one to two years later. The product is delivered as a SaaS subscription to hospitals, cancer centers, imaging networks, and organized screening programs.
Product overview
Therapixel offers a single unified product—MammoScreen®—an AI-powered medical imaging software for breast cancer screening. The software assists radiologists in interpreting both 2D mammography and 3D Digital Breast Tomosynthesis (DBT) exams by automatically detecting suspicious lesions and calcifications, scoring each finding on a 1-10 malignancy probability scale. MammoScreen represents the evolved form of the algorithm that won the Digital Mammography DREAM Challenge in 2017 and has since been enhanced with additional model families and prior exam analysis capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- MammoScreen® FDA-cleared and CE-marked AI-powered decision support software that assists radiologists in interpreting screening mammograms (both 2D and 3D/Digital Breast Tomosynthesis). The software automatically detects and characterizes suspicious lesions and calcifications, assigns a MammoScreen Score™ (1-10 scale) indicating malignancy probability, and leverages prior exam comparisons to detect cancers earlier. Targeted at hospitals, cancer centers, breast imaging practices, healthcare networks, and organized screening programs.
Quantifiable outcome
- Average AUC improved from 0.769 without AI to 0.797 with AI assistance (multi-reader multi-case study published in Radiology: AI)
- +4 more outcomes
Companies that use Therapixel
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles4 records
Therapixel technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature4 records
Therapixel partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and strategic.
- CureMetrixcoreIntegration partnership combining Therapixel's MammoScreen (breast cancer detection AI) with CureMetrix's cmAngio (FDA-cleared breast arterial calcification detection). The combined platform enables radiologists to screen for both breast cancer and breast arterial calcifications through a unified installation, expanding access to both AI solutions across healthcare providers.
- Onsite Women's HealthcoreStrategic partnership to deploy MammoScreen AI across Onsite Women's Health's national network of 150+ locations. The collaboration aims to enhance breast cancer detection and provide radiologists with AI-driven insights. Onsite serves patients across 26 states and has performed over 2 million exams since 2008. Both companies share a mission to improve outcomes for women through earlier cancer detection.
- Solutions ImagingstrategicCollaboration for prospective clinical study evaluating AI in second reading of screening mammograms in the PACA region of France. Solutions Imaging provides Gédéon software for dematerialization of mammography images for second reading, working with 8 radiology offices and CRCDC Sud PACA. The study involves 5,000 women and explores combining digital workflow with AI.
- CRCDC Sud PACAstrategicRegional cancer screening coordination center partnering in prospective clinical study for AI-assisted second reading. The study is the first French experiment in organized screening evaluating AI in second reading across 8 radiology offices.
- RAD-AID InternationalstrategicCollaboration to donate and support AI for making breast cancer screening more accessible in impoverished regions of the world. RAD-AID's partner sites in low and middle-income countries (LMICs) can receive Therapixel software through RAD-AID's educational collaborations. RAD-AID operates programs in 35 countries across Africa, Asia, Latin America and the Caribbean with over 12,000 volunteers.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Therapixel competitors and assessment
Company assessmentEmerging players
- DeepHealth (a RadNet company): DeepHealth, acquired by RadNet, develops AI tools for breast and broader radiology including mammography triage and Saige-Dx. With RadNet's imaging center footprint, it competes for AI-driven breast imaging workflows and is a scaled emerging player.
- Lunit: Lunit develops AI for mammography (Lunit INSIGHT MMG) and other cancer imaging, with growing US and European commercial presence. It is an emerging pure-play medical imaging AI vendor competing for similar hospital and screening program customers.
- Densitas: Densitas provides AI-powered breast density assessment and mammography quality analytics. It serves breast imaging centers with software that overlaps MammoScreen's clinical end users and complements some of the same screening workflows.
Broad incumbents
- Hologic: Hologic manufactures the dominant installed base of mammography systems in the US and offers Genius AI as part of its breast health portfolio. As the modality OEM, it competes with and could displace Therapixel at the point of purchase.
- GE HealthCare: GE HealthCare offers a broad radiology AI portfolio including mammography AI partnerships and its Edison platform. It can bundle AI into imaging equipment and enterprise contracts, putting Therapixel in competition with a much larger sales apparatus.
- Siemens Healthineers: Siemens Healthineers offers AI-Rad Companion and integrated mammography AI capabilities across its imaging portfolio. As an OEM and enterprise imaging vendor, it competes for the same hospital AI budget as Therapixel.
Direct peers
- Volpara Health Technologies: Volpara builds AI-driven breast imaging software including density assessment, risk prediction, and mammography reporting. It targets the same radiology and breast center customers as Therapixel with an overlapping product portfolio focused on breast cancer screening workflows.
- ScreenPoint Medical: ScreenPoint Medical offers Transpara, an AI system for breast cancer detection on 2D mammography and Digital Breast Tomosynthesis. It serves radiologists globally and competes head-to-head with MammoScreen on both modalities.
- iCAD Inc. iCAD markets ProFound AI, an FDA-cleared deep-learning mammography decision-support tool used by radiologists for breast cancer detection. It is one of the most direct competitive analogs to MammoScreen in clinical workflow and customer base.
- CureMetrix: CureMetrix markets cmAngio, an FDA-cleared AI for detecting breast arterial calcifications, and is a current integration partner of Therapixel. It addresses the same breast imaging customer base and could be both a partner and a competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Therapixel social profiles
Digital presenceTherapixel compliance and trust
Trust signalCompliance4 records
Therapixel financial estimates
Financial estimateRevenue estimate
Valuation estimate
Therapixel leadership team
Management profileNumber of profiles
Profiles6 records
Therapixel funding detail
Funding detailFunding overview
Funding rounds4 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Therapixel M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Therapixel
What does Therapixel do?
Therapixel develops and sells MammoScreen, an FDA-cleared and CE-marked AI software that assists radiologists in interpreting screening mammograms (both 2D and 3D/Digital Breast Tomosynthesis). The software automatically detects and characterizes suspicious lesions and calcifications, assigns a 1-10 MammoScreen Score representing malignancy probability, and uses prior exam comparisons to improve detection of cancers that would otherwise be diagnosed one to two years later. The product is delivered as a SaaS subscription to hospitals, cancer centers, imaging networks, and organized screening programs.
Is Therapixel a public or private company?
Therapixel is a private company. It is classified as venture growth investor backed and is currently operating.
When was Therapixel founded?
Therapixel was founded in 2013. It employs 51 to 100 people.
Where is Therapixel based?
Therapixel is headquartered in Nice, France, in the Europe region.
How does Therapixel make money?
One revenue line is on record: saaS Subscription Model.
Who are Therapixel's main competitors?
Emerging players on record are DeepHealth (a RadNet company), Lunit and Densitas. Broad incumbents are Hologic, GE HealthCare and Siemens Healthineers. Direct peers are Volpara Health Technologies, ScreenPoint Medical, iCAD Inc. and CureMetrix.
Does Therapixel have an API?
No public API is recorded for Therapixel.
What industry is Therapixel in?
Therapixel's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAHABAF, Mammography & Breast Imaging Systems. Its NAICS code is 3345 and its SIC code is 3841.